Stonegate Investment Group LLC Buys Shares of 33,838 Merck & Co., Inc. (NYSE:MRK)

Stonegate Investment Group LLC bought a new stake in Merck & Co., Inc. (NYSE:MRKGet Rating) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 33,838 shares of the company’s stock, valued at approximately $2,593,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Financial Avengers Inc. grew its position in shares of Merck & Co., Inc. by 115.8% in the fourth quarter. Financial Avengers Inc. now owns 328 shares of the company’s stock valued at $25,000 after purchasing an additional 176 shares in the last quarter. Moisand Fitzgerald Tamayo LLC grew its position in shares of Merck & Co., Inc. by 78.0% in the fourth quarter. Moisand Fitzgerald Tamayo LLC now owns 356 shares of the company’s stock valued at $27,000 after purchasing an additional 156 shares in the last quarter. Bellwether Advisors LLC grew its position in shares of Merck & Co., Inc. by 460.0% in the third quarter. Bellwether Advisors LLC now owns 420 shares of the company’s stock valued at $31,000 after purchasing an additional 345 shares in the last quarter. Ritter Daniher Financial Advisory LLC grew its position in shares of Merck & Co., Inc. by 33.9% in the fourth quarter. Ritter Daniher Financial Advisory LLC now owns 517 shares of the company’s stock valued at $40,000 after purchasing an additional 131 shares in the last quarter. Finally, Steward Financial Group LLC purchased a new position in shares of Merck & Co., Inc. in the fourth quarter valued at $40,000. Hedge funds and other institutional investors own 72.88% of the company’s stock.

Shares of NYSE MRK traded up $2.01 during midday trading on Tuesday, reaching $94.33. The company had a trading volume of 578,897 shares, compared to its average volume of 11,364,058. Merck & Co., Inc. has a one year low of $70.89 and a one year high of $92.87. The company has a quick ratio of 1.02, a current ratio of 1.27 and a debt-to-equity ratio of 0.80. The firm’s fifty day moving average price is $84.27 and its 200-day moving average price is $80.68. The stock has a market cap of $238.54 billion, a PE ratio of 16.52, a price-to-earnings-growth ratio of 1.22 and a beta of 0.37.

Merck & Co., Inc. (NYSE:MRKGet Rating) last released its earnings results on Thursday, April 28th. The company reported $2.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.83 by $0.31. Merck & Co., Inc. had a return on equity of 49.57% and a net margin of 26.27%. The company had revenue of $15.90 billion during the quarter, compared to analyst estimates of $14.64 billion. During the same quarter in the previous year, the company posted $1.40 EPS. Merck & Co., Inc.’s revenue for the quarter was up 31.6% on a year-over-year basis. As a group, equities research analysts expect that Merck & Co., Inc. will post 7.31 EPS for the current year.

Several equities analysts have recently weighed in on MRK shares. SVB Leerink reduced their price target on Merck & Co., Inc. from $100.00 to $97.00 and set an “outperform” rating for the company in a research report on Thursday, April 21st. Morgan Stanley reduced their target price on Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 6th. StockNews.com began coverage on Merck & Co., Inc. in a research report on Thursday, March 31st. They set a “strong-buy” rating for the company. Mizuho began coverage on Merck & Co., Inc. in a research report on Friday, April 1st. They set a “buy” rating and a $100.00 target price for the company. Finally, Barclays boosted their target price on Merck & Co., Inc. from $94.00 to $97.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 12th. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Merck & Co., Inc. presently has a consensus rating of “Buy” and a consensus target price of $90.69.

Merck & Co., Inc. Profile (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

See Also

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.